Original Article

Evaluating Adequacy of VTE Prophylaxis Dosing with Enoxaparin for Overweight and Obese Patients on an Orthopedic-Medical Trauma Comanagement Service

Authors: Ann Perrin, MD, MPH, Heena Sheth, MD, MPH, Victoria Snyder, PA, Hannah Dailey, MS, Franziska Jovin, MD, MMM, Roy Smith, MD

Abstract

Objectives: Venous thromboembolism (VTE) is a common nosocomial condition, developing frequently in overweight and obese patients. VTE prophylaxis with weight-based enoxaparin dosing may be more effective than the standard dosing regimen for overweight and obese patients; however, weight-based dosing is not practiced routinely. In this pilot study we sought to evaluate prophylactic anticoagulation regimens used for VTE prevention in overweight and obese patients on the Orthopedic-Medical Trauma (OMT) service to inform the need for modification of dosing practices.

Methods: This prospective, observational study evaluated the adequacy of current VTE prophylaxis practice at an academic tertiary center, including overweight and obese patients admitted during 2017–2018 to an OMT comanagement service. It included patients hospitalized for at least 3 days with a body mass index (BMI) of ≥25 and prescribed enoxaparin. Steady-state antifactor Xa trough and peak levels were monitored after three doses. Frequency of in prophylactic range (0.2–0.44) antifactor Xa levels and VTE events were compared by BMI groups and enoxaparin dosing using the χ2 test.

Results: There were 404 inpatients included: 41.1% were overweight (BMI 25–29), 43.4% were obese (BMI 30–39), and 15.6% were morbidly obese (BMI ≥40). A total of 351 patients (86.9%) received standard dose enoxaparin 30 mg 2 times per day (BID), and 53 patients received enoxaparin 40 mg BID or more. A number of patients (213; 52.7%) did not achieve prophylactic range antifactor Xa levels. A significantly higher number of patients in the overweight group achieved prophylactic range antifactor Xa compared with obese and morbidly obese groups (58.4% vs 41.7% and 33%, P = 0.002 and 0.0007, respectively). Morbidly obese patients treated with enoxaparin 40 mg BID or higher versus enoxaparin 30 mg BID had fewer VTE events (4% vs 10.8%, P = 0.18).

Conclusions: The current practice of VTE enoxaparin prophylaxis may not be adequate for overweight and obese OMT patients. Further guidelines are needed to implement weight-based VTE prophylaxis in overweight and obese hospitalized patients.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007;44:62–69.
 
2. Phillippe HM. Overview of venous thromboembolism. Am J Manag Care 2017;23:S376–S382.
 
3. Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res 2016;(137):3–10.
 
4. Jupalli A, Iqbal AM. Enoxaparin. Treasure Island, FL: StatPearls Publishing; 2020.
 
5. Geerts W, Jay R, Code K, et al. Comparison of low-dose heparin with low-molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701–707.
 
6. Costantini TW, Min E, Box K, et al. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg 2013;74:128–135.
 
7. Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011;37:903–907.
 
8. Hirsch J, Raschke R. Heparin and low molecular weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2007;(126):188S–203S.
 
9. Garcia DA, Baglin TP, Weitz J, et al. Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 suppl):e24S–e43S.
 
10. Levine MN, Planes A, Hirsch J, et al. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent DVT after hip replacement. Thrombo Hemast 1989;62:940–944.
 
11. Malinoski D, Jafari F, Ewing T, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 2010;68:874–880.
 
12. Bates SM, Greer IA, Middledorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 suppl):e691S–e736S.
 
13. Egan G, Ensom MH. Measuring anti-factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm 2015;68:33–47.
 
14. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Advances 2018;2:3257–3291.
 
15. Shaikh S, Boneva D, McKenney M, et al. Venous thromboembolism chemoprophylaxis regiments in trauma and surgery patients with obesity: a systematic review. J Trauma Acut Care Surg 2020;88:522–535.
 
16. Mansoor A, Mahabadi N. Volume of Distribution. Treasure Island, FL: StatPearls Publishing; 2021.
 
17. Ko A, Harada MY, Barmparas G, et al. Association between enoxaparin dosage adjustment by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma. JAMA Surg 2016;151:1006–1013.
 
18. Heit J. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12:464–474.
 
19. Nunez JM, Becher RD, Rebo GJ, et al. Prospective evaluation of weight-based prophylactic enoxaparin dosing in critically ill trauma patients: adequacy of anti-Xa level is improved. Am Surg 2015;82:605–609.
 
20. Maclachlan KH, Stevens HP, Chunilal SD et al. Weight-based enoxaparin dosing for venous thromboembolism (VTE) >100 kg gives similar anti-Xa levels to patients <100 kg, with no increase in bleeding. Blood 2018;132(S1):5059.
 
21. Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 2019;4:163–173.